Clinical trials: Moderate COVID-19-infection, open to volunteers
COVID-19
RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19
This is a randomized, double-blinded, placebo-controlled clinical trial. This study is to evaluate the effectiveness and safety of Yinqiaosan-Maxingganshitang in the treatment of the major symptoms of mild and moderate COVID-19…
- Trial name
- NCT05787327
- Testing
- Chinese Herb
- Where
- Hong Kong
- Volunteers
- 96 people
- Sponsor
- Chinese University of Hong Kong
COVID-19, Thermotherapy
Local Thermotherapy for Patients With Mild-to-moderate COVID-19
The etiological agent of the current pandemic is a (+)ssRNA virus. SARS-CoV-2 is infecting thousands of people in the world with a fatality rate that varies from 0.1 to 5% in affected countries, thereby causing enormous economic…
- Trial name
- TherMoCoV (NCT04363541)
- Testing
- Electric pad for human external pain therapy
- Where
- 3 sites in Mexico
- Volunteers
- 274 people
- Sponsor
- Instituto Nacional de Perinatologia
COVID-19
Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms
Investigational New Drug trial investigating safety as primary endpoint and clinical efficacy as secondary endpoint of placental, mesenchymal stem cell-derived extracellular vesicles for the treatment of COVID-19 symptoms in…
- Trial name
- NCT07664696
- Testing
- IV infusion using an isolated, placental, mesenchymal stem cell derived EVs
- Volunteers
- 64 people
- Sponsor
- Kimera Labs Inc.
Covid19
SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease
The 2019 Severe Acute Respiratory Syndrome (SARS) is a global pandemic secondary to a novel coronavirus - SARS-CoV-2. The reported case-fatality ratio for SARS-CoV-2 in the United States is 1.8% with a current death toll of…
- Trial name
- NCT04896606
- Testing
- Standard of Care, SARS-CoV2-CTLS
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- New York Medical College
Covid19, Corona Virus Infection
SPI-1005 Treatment in Moderate COVID-19 Patients
The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and moderate symptoms of COVID-19…
- Conditions
- Covid19, Corona Virus Infection, Coronavirus, Coronavirus Infection
- Trial name
- NCT04484025
- Testing
- Ebselen
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sound Pharmaceuticals, Incorporated